Linco Research

Linco Research develops and provides specialized immunoassay products for the scientific community, focusing on tools that facilitate research using both human and animal specimens. The company’s core offering centers on the meticulous development and performance of assay kits, enabling researchers to accurately measure various biological markers. These solutions are designed to support rigorous investigation across diverse fields.

The company was founded in 1978 by Ronald Gingerich, who established the enterprise with an acute understanding of the scientific community's need for precise and reliable diagnostic and research tools. Gingerich's initial vision stemmed from a commitment to creating highly specific assays that could directly address the evolving demands of scientific inquiry, particularly in complex biological systems.

Linco Research serves a global network of scientists and researchers requiring advanced analytical capabilities for their studies. The company's long-term vision is anchored in continuously advancing its assay technologies and expanding its diagnostic offerings, thereby empowering researchers to uncover new insights and push the boundaries of biological and medical understanding.

High-Level Overview

LINCO Research is a life sciences company that manufactures and markets proprietary immunoassay kits for the drug discovery and development industry.[1][2][4] Based in St. Charles, Missouri (with earlier references to St. Louis), it specializes in reagents and kits for detection in medical testing, clinical laboratories, and healthcare applications, including quantitative assays like human C-peptide radioimmunoassays for serum, plasma, and tissue culture media.[3][7] The company served pharmaceutical and biotech researchers by providing tools for analyzing human and animal research specimens, with reported revenue around $8.4 million at one point.[3][6]

LINCO consisted of two main entities: LINCO Research Inc. (LRI), focused on manufacturing immunoassay kits, and LINCO Diagnostic Services, Inc. (LDS).[5] It addressed key needs in preclinical and clinical research by offering specialized, proprietary immunoassays developed over more than 20 years.[6]

Origin Story

LINCO Research operated for over 20 years, developing and performing immunoassays for human and animal research specimens, with expertise offered to drug discovery sectors.[6] The company was headquartered in St. Charles (and previously St. Louis), Missouri, establishing itself as a manufacturer of reagents and kits.[2][3][5] A pivotal moment came when Serologicals Corporation agreed to acquire LINCO in a $74.8 million deal, highlighting its value in the life sciences space; the acquisition encompassed both LRI and LDS.[5] Specific founding year and founders are not detailed in available records, but its longevity underscores steady growth in immunoassay technology.[1][4]

Core Differentiators

• Proprietary Immunoassay Kits: Specialized in custom, high-precision kits like the Human C-Peptide radioimmunoassay for quantitative detection in serum, plasma, and tissue media, tailored for drug development.[1][4][7]
• Focus on Research Applications: Over 20 years of expertise in human and animal specimen analysis, providing detection tools for preclinical and discovery phases.[6]
• Dual Structure: Combined manufacturing (LRI) with diagnostic services (LDS), offering end-to-end solutions for biotech and pharma.[5]
• Regional Manufacturing Strength: U.S.-based (Missouri) production of medical supplies, supporting reliable supply for clinical labs.[2][3]

Role in the Broader Tech Landscape

LINCO Research rode the wave of advancing drug discovery tools in the 1990s and early 2000s, when immunoassays became essential for biomarker detection in preclinical testing amid rising biotech investments.[1][6] Its timing aligned with growth in biopharma R&D, where precise measurement of peptides and proteins accelerated candidate validation. Market forces like demand for animal model research and outsourcing of assay development favored specialized providers like LINCO.[4][5] The $74.8 million acquisition by Serologicals amplified its influence, integrating its kits into larger platforms and contributing to consolidated life sciences tooling ecosystems.[5]

Quick Take & Future Outlook

LINCO Research exemplified niche innovation in immunoassay tech, culminating in a high-value acquisition that validated its role in drug development pipelines.[5] Post-acquisition, its technologies likely evolved within Serologicals (now part of larger entities like MilliporeSigma), influencing modern biomarker assays amid trends like AI-driven discovery and personalized medicine. Future impact may lie in legacy contributions to high-throughput screening, as demand for precise, scalable detection grows with complex biologics and gene therapies—positioning its foundational kits as enduring enablers in an increasingly integrated biopharma landscape.